Advising J.P. Morgan Securities plc on Acquisition of Avadel Pharmaceuticals by Alkermes
We are pleased to be advising J.P. Morgan Securities plc, as financial adviser to the buyer, on the proposed acquisition of Avadel Pharmaceuticals plc by Alkermes plc. The transaction is valued at up to $2.37 billion.
Avadel is an Irish-incorporated, Nasdaq-listed biopharmaceutical company best known for Lumryz, its FDA-approved treatment for narcolepsy. Alkermes, also listed on Nasdaq, is an Irish-headquartered global biopharmaceutical company. The transaction is being implemented by way of a recommended scheme of arrangement under Irish law and remains subject to shareholder and regulatory approvals.
We have advised on the majority of recent takeovers of Irish public companies, including acting for bidders, targets and cash-confirming financial advisers.
The transaction team is being led by Corporate Partners Anne Harkin and Justin McKenna, with support from Associates Gareth Black and Dean Molyneaux and Trainee India Kelly.
For information and expert advice on similar Life Sciences sector mandates, please reach out us.
Share this: